Apoptosis in prostate cancer: Bax correlation with stage
- 1 April 2005
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 12 (4) , 340-345
- https://doi.org/10.1111/j.1442-2042.2005.01051.x
Abstract
Dysregulation of apoptosis may contribute to the process of prostate tumorigenesis by reducing the rate of cell death. Bcl-2 and bax are important molecules involved in the regulation of apoptosis. The aim of the present study is to examine apoptosis and related regulatory molecular markers in a group of Iranian patients with prostate cancer. Paraffin-embedded tissues from 50 patients of prostate carcinoma were examined for the expression of bcl-2 antiapoptotic and bax proapoptotic markers and also proliferation marker, Ki-67, by immunohistochemistry. Detection of apoptotic cells was performed using TUNEL method. Correlation between apoptotic index, proliferation index and bcl-2 and bax expression with stage, pathological grade and Gleason score was determined. Apoptosis was detected in 12% of prostate cancers. No correlation was observed between apoptosis and differentiation status of carcinoma. Bcl-2 expression was detected in 21 of samples. A significant correlation between bcl-2 expression and Ki-67 staining index (r = 0.349, P = 0.012) was observed. High bax protein expression was shown in our study. We found a significant correlation between bax expression and stage of carcinoma (r = 0.388, P = 0.031), but not with the apoptosis index, suggesting the presence of a non-functional bax protein or the role of other proapoptotic molecules. The patients in the present study showed a different pattern of apoptosis positivity compared to other reports. Bax expression may be a useful marker for prognosis of prostate cancer.Keywords
This publication has 18 references indexed in Scilit:
- Prostate CancerNew England Journal of Medicine, 2003
- Prostate cancer: a dynamic illness with shifting targetsThe Lancet Oncology, 2003
- Regulation of apoptosis by Bcl‐2 family proteinsJournal of Cellular and Molecular Medicine, 2003
- Molecular markers of outcome after radiotherapy in patients with prostate carcinomaCancer, 2003
- BCL-2 in prostate cancer: A minireviewApoptosis, 2003
- Apoptosis and tumourigenesisCurrent Opinion in Genetics & Development, 2002
- Activation-induced cell deathCurrent Opinion in Immunology, 2001
- Molecular Mechanisms of Androgen-Independent Growth of Human Prostate Cancer LNCaP-AI CellsEndocrinology, 1999
- BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with BaxNature, 1994
- Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic CarcinomaBritish Journal of Urology, 1993